Literature DB >> 29180001

Effect of the FE2+ chelation by 2,2'-dipyridyl in the doxorubicin-induced lethality in breast tumor cell lines.

Jéssica R Bernardes1, Caroline C Faria1, Iris S Andrade1, Andrea Claudia Freitas Ferreira2, Denise P Carvalho2, Alvaro C Leitão1, Tatiana A M de Alencar1, Rodrigo S Fortunato3.   

Abstract

Breast cancer cells may exhibit changes in iron homeostasis, which results in increased labile iron pool (LIP) levels. Several studies highlight the crucial role of high LIP levels in the maintenance of tumor cell physiology. Iron chelators have been tested in anticancer therapy in combination with chemotherapeutic agents, to improve drug efficacy. Thus, the aim of this study was to evaluate the effect of 2,2'-dipyridyl (DIP), a Fe2+ chelator, in combination with doxorubicin (DOX) in breast tumor cells. The maximum concentration of DIP that did not significantly reduce the viability of MDA-MB-231 cells was 10μM and for MCF-7 cells was 50μM. We observed that MCF-7 had higher LIP levels than MDA-MB-231 cells. DIP alone increased ROS generation in MCF-7 cells, and DIP pretreatment reduced ROS generation induced by DOX treatment. In conclusion, the increase in MCF-7 cell viability induced by DIP pretreatment in DOX-treated cells seems to be related to an increase in the cellular antioxidant capacity and the iron chelator did not improve drug efficacy in the two breast tumor cell lines analyzed.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Dipyridyl; Iron; Reactive oxygen species

Mesh:

Substances:

Year:  2017        PMID: 29180001     DOI: 10.1016/j.lfs.2017.11.038

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

Review 1.  Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.

Authors:  Rachel E Nicoletto; Clyde M Ofner
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-12       Impact factor: 3.333

2.  Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target.

Authors:  Yasutaka Yamada; Mayuko Kato; Takayuki Arai; Hiroki Sanada; Akifumi Uchida; Shunsuke Misono; Shinichi Sakamoto; Akira Komiya; Tomohiko Ichikawa; Naohiko Seki
Journal:  Mol Oncol       Date:  2019-06-27       Impact factor: 6.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.